Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
Submitted by
admin
on January 12, 2018 - 10:39am
Source:
Endpoints
News Tags:
AstraZeneca
PARP inhibitors
FDA
Lynparza
metastatic breast cancer
Headline:
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
Do Not Allow Advertisers to Use My Personal information
